<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572260</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000856</org_study_id>
    <secondary_id>19497</secondary_id>
    <nct_id>NCT00572260</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Daptomycin for Antimicrobial Prophylaxis</brief_title>
  <official_title>A Pilot Study of Daptomycin for Antimicrobial Prophylaxis in Patients Undergoing Cardiac Valve Replacement and Coronary Artery Bypass Grafting (CABG) Who Are at Increased Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus (MRSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of the study are to evaluate the feasibility of using daptomycin as a prophylactic
      antimicrobial agent in patients undergoing cardiac surgery, to determine the rates of
      surgical site infection, and to evaluate the occurrence of adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed. PI left the institution.
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Patients Receiving Antimicrobial Prophylaxis Within the Appropriate Timeframe Before Incision</measure>
    <time_frame>30 days after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Antimicrobial Prophylaxis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daptomycin as a single preoperative dose within 30 minutes prior to surgery Dosage: if creatinine clearance ≥ 30 ml/min: 6 mg/kg IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daptomycin 6 mg/kg IV</intervention_name>
    <description>daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA: Patients will be eligible for inclusion in the study if they meet the
        following criteria:

          1. Provide signed and dated informed consent and are willing to receive the study
             medication

          2. Age ≥ 18 years of age

          3. If a female of childbearing potential is willing to practice at least one method of
             birth control during treatment and for at least 28 days after treatment with study
             medication:

               1. barrier methods of birth control (e.g., condoms, diaphragms together with
                  spermicidal foam or gel, or presence of IUD) or

               2. surgical sterilization, approved hormonal contraceptives (such as birth control
                  pills, depo-Provera, or Lupron Depot), or IUD are all acceptable.

                    -  Rhythm, temperature, and verbal promise of abstinence are not acceptable
                       methods of birth control.

          4. If a female of childbearing potential, serum HCG negative within 24 hours of scheduled
             surgery.

          5. Planned cardiac surgery procedures meeting current Duke criteria to receive
             anti-microbial prophylaxis active against MRSA:

             a. Patients will meet at least one of the following criteria which are the same as for
             prophylaxis with vancomycin: i. preoperative hospitalization &gt; 48 hours ii. transfer
             to Duke from outside facility iii. previous history of MRSA iv. any patient deemed to
             be high risk for MRSA by the attending surgeon, due to a complicated past medical
             and/or surgical history

        EXCLUSION CRITERIA: Patients who satisfy any of the following are not eligible for study
        enrollment.

          1. Hypersensitivity to daptomycin

          2. Inability to receive standard prophylaxis agents (cefuroxime and rifampin) for any
             reason

          3. Staphylococcal bacteremia at the time of enrollment

          4. Diagnosis of S. aureus or coagulase negative staphylococcus pacemaker/defibrillator
             infection within the preceding 18 months

          5. Patient is undergoing emergency CABG

          6. Weight &gt;150 kg or &lt;50kg

          7. Patients considered unlikely to survive at least 7 days due to underlying illness.

          8. Patients with creatinine clearance (CLcr) &lt; 30mL/min (calculated using the
             Cockcroft-Gault equation using actual body weight)

          9. Severe neutropenia (absolute neutrophil count &lt;0.500x103 /µL)

         10. Pregnant, nursing or lactating women (if patient is still of childbearing potential, a
             negative serum pregnancy test will be confirmed)

         11. Patients considered unlikely to comply with study procedures or to return for the
             scheduled post treatment evaluation

         12. Any other condition that in the opinion of an investigator, would confound or
             interfere with evaluation of safety or efficacy of the investigational medication, or
             prevent compliance with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith S Kaye, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>DMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <results_first_submitted>March 29, 2011</results_first_submitted>
  <results_first_submitted_qc>November 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2012</results_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRSA</keyword>
  <keyword>Increased risk for infection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Methicillin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 1/17/2008 and 9/15/2008, 124 subjects were identified as qualifying, 56 were referred and approached, 44 refused to participate, and 12 signed the ICF at Duke University Hospital inpatient care units.</recruitment_details>
      <pre_assignment_details>Between 1/17/2008 and 9/15/2008, among the 12 study subjects that signed the ICF, 11 subjects met the eligibility criteria and were enrolled in the study. One subject was disqualified due to weight &gt; 150kg and was withdrawn from the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Antimicrobial Prophylaxis Administration With Daptomycin</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antimicrobial Prophylaxis Administration With Daptomycin</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Patients Receiving Antimicrobial Prophylaxis Within the Appropriate Timeframe Before Incision</title>
        <time_frame>30 days after surgery</time_frame>
        <population>The study closed due to the departure of the principal investigator and the data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Undergoing Cardiac Surgery</title>
            <description>Patients undergoing cardiac valve replacement and coronary artery bypass grafting</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Patients Receiving Antimicrobial Prophylaxis Within the Appropriate Timeframe Before Incision</title>
          <population>The study closed due to the departure of the principal investigator and the data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Antimicrobial Prophylaxis Administration With Daptomycin</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Premature termination of the study due to departure of the PI resulted in falling short of enrollment goal (enrolled - 11 enrolled/goal - 100) leading to uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Yong Choi, Clinical Research Coordinator</name_or_title>
      <organization>Duke University Health System</organization>
      <phone>919-684-7584</phone>
      <email>yong.choi@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

